• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Hyperion DeFi Inc.

    8/18/25 5:15:08 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email
    S-8 1 tm2523405d1_s8.htm FORM S-8

      

    As filed with the Securities and Exchange Commission on August 18, 2025

    Registration No. 333-_____

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    HYPERION DEFI, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   47-1178401
    (State or other jurisdiction of incorporation or
    organization)
      (I.R.S. Employer Identification No.)
         
    23461 S. Pointe Drive, Suite 390    
    Laguna Hills, CA 92653   10017
    (Address of Principal Executive Offices)   (Zip Code)

     

    Hyperion DeFi, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan, as Amended

    Hyperion DeFi, Inc. Restricted Stock Unit Inducement Award

    (Full titles of the plans)

     

    Michael Rowe

    Chief Executive Officer

    23461 S. Pointe Drive, Suite 390

    Laguna Hills, CA 92653

    (833) 393-6684

    (Name, address and telephone number, including area code, of agent for service)

     

    Copy:

     

    Megan N. Gates

    Covington & Burling LLP

    1 International Place

    Boston, MA 02110

    (617) 603-8805

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement registers an aggregate of 5,672,934 additional shares of common stock, par value $0.0001 per share (“Common Stock”), of Hyperion DeFi, Inc. (the “Company” or the “Registrant”), consisting of (i) 5,172,934 shares of Common Stock issuable pursuant to the Hyperion DeFi, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan, as amended, representing an increase of 5,172,934 shares of Common Stock reserved for issuance under such plan, as a result of an amendment thereto, which was adopted by the board of directors of the Company on June 26, 2025 and approved by the Company’s stockholders at the Annual Meeting of Stockholders held on August 18, 2025; and (ii) 500,000 shares of Common Stock issuable upon the vesting of restricted stock units (“RSUs”) granted to Hyunsu Jung as an inducement to employment with the Company pursuant to Nasdaq Listing Rule 5635(c)(4), which RSUs vested on June 17, 2025.

     

    Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, the contents of the Registrant’s Registration Statements on Form S-8 filed with the U.S. Securities and Exchange Commission (the “Commission”) on August 27, 2018 (File No. 333-227049), August 14, 2019 (File No. 333-233280), August 14, 2020 (File No. 333-246288), November 12, 2021 (File No. 333-261035), August 12, 2022 (File No. 333-266823), June 27, 2023 (File No. 333-272962), and March 5, 2025 (333-285583) are incorporated by reference and made part of this Registration Statement. Any items in such registration statements not expressly changed hereby shall be as set forth in such registration statements.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Company is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) and in accordance therewith files reports, proxy statements and other information with the Commission. The following documents, which are on file with the Commission, are incorporated in this Registration Statement by reference:

     

    (a) The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on April 15, 2025 (File No. 001-38365), as amended by the Company’s Amendment No. 1 to Annual Report on Form 10-K, filed with the Commission on April 30, 2025;

     

    (b) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the document referred to in (a) above (other than the portions of those documents not deemed to be filed); and

     

    (c) The description of the Company’s Common Stock contained in Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on April 15, 2025 (File No. 001-38365).

     

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents.

     

     

     

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    Exhibit
     No.
    Description
       
    4.1 Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on January 29, 2018).
       
    4.2 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1.1 of the Registrant’s Current Report on Form 8-K filed on June 14, 2018).
       
    4.3 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on June 14, 2024).
       
    4.3 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on January 31, 2025).
       
     4.4 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on July 2, 2025).
       
    4.5 Second Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on February 7, 2022).
       
    4.6 Hyperion DeFi, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan, as Amended (incorporated herein by reference to Appendix C of the Registrant’s Proxy Statement on Schedule 14A, filed on July 24, 2025).
       
    5.1* Opinion of Covington and Burling LLP.
       
    23.1* Consent of Marcum LLP.
       
    23.2* Consent of Covington and Burling LLP (included in Exhibit 5.1).
       
    24.1* Power of Attorney (included on the signature page of this Registration Statement).
       
    107* Filing Fees Exhibit.

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Laguna Hills, State of California, on August 18, 2025.

     

      HYPERION DEFI, INC.
       
      By:  /s/ Michael Rowe
        Michael Rowe
        Chief Executive Officer

     

    SIGNATURES AND POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Michael Rowe as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Michael Rowe   Chief Executive Officer
    (Principal Executive Officer) and Director
      August 18, 2025
    Michael Rowe
             
    /s/ Michael Rowe   Principal Financial Officer
    (Principal Financial and Accounting Officer)
      August 18, 2025
    Michael Rowe
     
    /s/ Michael Geltzeiler   Director   August 18, 2025
    Michael Geltzeiler
             
    /s/ Rachel Jacobson   Director   August 18, 2025
    Rachel Jacobson
             
    /s/ Hyunsu Jung   Director   August 18, 2025
    Hyunsu Jung
             
    /s/ Ellen R. Strahlman   Director   August 18, 2025
    Ellen R. Strahlman

     

     

     

    Get the next $HYPD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HYPD
    SEC Filings

    View All

    Hyperion DeFi Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    9/29/25 5:06:46 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by Hyperion DeFi Inc.

    S-3/A - HYPERION DEFI, INC. (0001682639) (Filer)

    9/26/25 5:53:05 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Hyperion DeFi Inc.

    424B5 - HYPERION DEFI, INC. (0001682639) (Filer)

    9/24/25 7:21:26 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

    PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced the appointment of David Knox, CFA, as Chief Financial Officer, effective immediately. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company's decentralized finance ("DeFi") strateg

    9/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Adds $10M in HYPE to its Treasury Holdings

    LAGUNA HILLS, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), today announced that it has acquired an additional 176,422 HYPE tokens, expanding its total holdings to 1,712,195 HYPE purchased at an average price of $38.25 per token. "The Hyperliquid ecosystem continues to demonstrate the central role that HYPE has in both on-chain governance and enabling the associated governance outcomes, as seen with the recent USDH stablecoin proposals," said Hyunsu Jung, Interim Chief Executive Officer. "Following the upcoming mainnet upgrade, a minimum stake of 200,000 HYPE will be required to qualify as an eligible quote asset on Hyper

    9/25/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

    LAGUNA HILLS, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced its first HYPE Asset Use Service ("HAUS") agreement with proprietary trading firm Credo Cayman ("Credo"). Through this first-of-its-kind on-chain service, Hyperion DeFi provides the use of 100,000 staked HYPE to Credo, enabling the firm to substantially reduce transaction fees when trading on Hyperliquid. The resulting net fee savings will be shared between the two companies, creating a new revenue stream for both. "Hyperion DeFi's l

    9/16/25 8:00:39 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Walters Happy David was granted 50,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    9/9/25 4:08:07 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Walters Happy David

    3 - HYPERION DEFI, INC. (0001682639) (Issuer)

    9/9/25 4:07:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Jung Hyunsu was granted 1,000,000 shares, increasing direct ownership by 200% to 1,500,000 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    8/20/25 4:49:06 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Leadership Updates

    Live Leadership Updates

    View All

    Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

    PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced the appointment of David Knox, CFA, as Chief Financial Officer, effective immediately. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company's decentralized finance ("DeFi") strateg

    9/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care